APAC Obesity Pipeline Hits 30 Assets as Orforglipron and Two Asian Approvals Reshape GLP-1 Race
A BioPharma APAC census finds 30 Asia-Pacific-discovered obesity assets in human trials, 21 from mainland China, with three 2026 approvals and three Chinese GLP-1/GIP duals filed with the…
Read article →